Redeye comments on OncoZenge’s recent amendment to its licensing agreement with Molteni Farmaceutici...
Cereno Scientific reported positive Phase I readouts for CS014, its novel HDAC inhibitor, paving the...
Hansa is better positioned to support its main value drivers, engage in strategic priorities, and po...
Q2'25 details Prevas reports Q2'25 sales of SEK 409m (-4% vs.
Redeye sees a soft Q2 report from Stille, marked by headwinds in the surgical instruments business, ...
Q2'25 report The Q2 report was below expectations on both sales and adj.
Q2 in brief: report in line, good gross margin Embellence Group's Q2 report is in line overall.
Redeye comments on Evolutions Q2-results, which were in line with our expectations, albeit with slig...
Redeye provides its first take on Camurus’ Q2 report 2025, published this morning.
Following the profit warning on 12 June, Fiskars Q2 adjusted EBIT of EUR 3.
Redeye remains confident on the case and leave our forecasts and valuation virtually unchanged follo...
Redeye believes Enea’s share price has further to run following the positive market reaction to its ...
Redeye updates its estimates and valuation for Serstech following the Q2 2025 report.
Redeye comments on Freemelt ahead of its Q2 results.
Solid order bookings given a cautious market The Q2 report showed lower sales than we expected, as w...
Servicebolaget Coor rapporterade ett starkt kvartal som överträffade vår prognos.
Redeye comments on the conversion of warrants and Cantargia's deal yesterday.
Q2'25 impressions Nilörn reports Q2'25 sales of SEK 237m (-3% vs.
Oriola More cautious stance on Wholesale profitability Oriola reports its Q2 results on July 18th.
Redeye comments on the news that the FDA has granted ACD440 orphan drug designation (ODD) for the tr...
